ArticleResearch square2026
HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
We conducted a first-in-human evaluation of HIV-specific, HIV-resistant chimeric antigen receptor (CAR) T cells (CARTs) to determine their capacity to modulate viral rebound dynamics following analytic treatment interruption (ATI). Among ten treated individuals who received engineered T cells, one individual did not rebound during the ATI and had a remarkable expansion of their CARTs 43 days after the start of the ATI, suggesting that the CARTs recognized rebounding HIV and prevented its spread. Post-rebound virologic control was observed in 1 participant for 90 weeks and another 5 participants had remarkable reductions in their viral load after viral peak was reached, maintaining viral loads below their set point. CART infusion was associated with broad reinvigoration of endogenous HIV-specific CD8 T cell responses, and immune escape to one of these responses was documented. Together, these findings show that HIV-specific CARTs can be an integral component in HIV Cure strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.